Combined peripheral natural killer cell and circulating tumor cell enumeration enhance prognostic efficiency in patients with metastatic triple-negative breast cancer

被引:15
|
作者
Liu, Xiaoran [1 ]
Ran, Ran [1 ]
Shao, Bin [1 ]
Rugo, Hope S. [2 ]
Yang, Yanlian [3 ]
Hu, Zhiyuan [3 ]
Wei, Zewen [3 ]
Wan, Fengling [1 ]
Kong, Weiyao [1 ]
Song, Guohong [1 ]
Jiang, Hanfang [1 ]
Liang, Xu [1 ]
Zhang, Ruyan [1 ]
Yan, Ying [1 ]
Xu, Guobing [4 ]
Li, Huiping [1 ]
机构
[1] Peking Univ, Key Lab Carcinogenesis & Translat Res, Minist Educ Beijing, Dept Breast Oncol,Canc Hosp & Inst, Beijing 100142, Peoples R China
[2] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94115 USA
[3] Chinese Acad Sci, Key Lab Standardizat & Measurement Nanotechnol, Natl Ctr Nanosci & Technol China, Beijing 100190, Peoples R China
[4] Peking Univ, Key Lab Carcinogenesis & Translat Res, Minist Educ Beijing, Dept Clin Lab,Canc Hosp & Inst, Beijing 100142, Peoples R China
基金
中国国家自然科学基金;
关键词
Breast cancer; nanotechnology; circulating tumor cell; immunology; MOLECULAR SUBTYPES; DENDRITIC CELLS; IMMUNE-SYSTEM; NK-CELLS; T-CELLS; EXPRESSION; BLOOD; PHENOTYPE;
D O I
10.21147/j.issn.1000-9604.2018.03.04
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: Triple-negative breast cancer (TNBC) is a heterogeneous disease with poor prognosis. Circulating tumor cells (CTCs) are a promising predictor for breast cancer prognoses but their reliability regarding progression-free survival (PFS) is controversial. We aim to verify their predictive value in TNBC. Methods: In present prospective cohort study, we used the Pep@MNPs method to enumerate CTCs in baseline blood samples from 75 patients with TNBC (taken at inclusion in this study) and analyzed correlations between CTC numbers and outcomes and other clinical parameters. Results: Median PFS was 6.0 (range: 1.0-25.0) months for the entire cohort, in whom we found no correlations between baseline CTC status and initial tumor stage (P=0.167), tumor grade (P=0.783) or histological type (P=0.084). However, among those getting first-line treatment, baseline CTC status was positively correlated with ratio of peripheral natural killer (NK) cells (P=0.032), presence of lung metastasis (P=0.034) and number of visceral metastatic site (P=0.037). Baseline CTC status was predictive for PFS in first-line TNBC (P=0.033), but not for the cohort as a whole (P=0.118). This prognostic limitation of CTC could be ameliorated by combining CTC and NK cell enumeration (P=0.049). Conclusions: Baseline CTC status was predictive of lung metastasis, peripheral NK cell ratio and PFS in TNBC patients undergoing first-line treatment. We have developed a combined CTC-NK enumeration strategy that allows us to predict PFS in TNBC without any preconditions.
引用
收藏
页码:315 / +
页数:15
相关论文
共 50 条
  • [41] Novel prognostic markers for patients with triple-negative breast cancer
    Zhou, Ling
    Li, Ke
    Luo, Yanli
    Tian, Ling
    Wang, Min
    Li, Chuanyuan
    Huang, Qian
    HUMAN PATHOLOGY, 2013, 44 (10) : 2180 - 2187
  • [42] PROGNOSTIC IMPACT OF CIRCULATING TUMOR CELL CLUSTERS AND APOPTOSIS IN METASTATIC BREAST CANCER
    Jansson, Sara
    Bendahl, Par-Ola
    Larsson, Anna-Maria
    Aaltonen, Kristina
    Ryden, Lisa
    BREAST, 2015, 24 : S71 - S71
  • [43] The prognostic impact of age in patients with triple-negative breast cancer
    Liedtke, Cornelia
    Hess, K. R.
    Karn, T.
    Rody, A.
    Kiesel, L.
    Hortobagyi, G. N.
    Pusztai, L.
    Gonzalez-Angulo, A. M.
    BREAST CANCER RESEARCH AND TREATMENT, 2013, 138 (02) : 591 - 599
  • [44] The prognostic impact of age in patients with triple-negative breast cancer
    Cornelia Liedtke
    K. R. Hess
    T. Karn
    A. Rody
    L. Kiesel
    G. N. Hortobagyi
    L. Pusztai
    A. M. Gonzalez-Angulo
    Breast Cancer Research and Treatment, 2013, 138 : 591 - 599
  • [45] Importance of circulating tumor DNA analysis at diagnosis in early triple-negative breast cancer patients
    Park, Min-Seung
    Cho, Eun Hye
    Youn, Youngjin
    Do, In-Gu
    Woo, Hee-Yeon
    Park, Hyosoon
    Kim, Eun Young
    Kwon, Min-Jung
    BREAST CANCER, 2025, 32 (02) : 416 - 425
  • [46] Dynamic monitoring of circulating tumor DNA can predict chemotherapy response and prognosis in metastatic triple-negative breast cancer patients
    Li, Huihui
    Chi, Yajing
    Yin, Sha
    Yu, Bo
    Su, Mu
    Zhang, Baoxuan
    Qiang, Ling
    Ren, Guohua
    Song, Lihua
    Bu, Bing
    Fang, Shu
    Shang, Mao
    Tan, Qiaorui
    Man, Xiaochu
    CANCER RESEARCH, 2022, 82 (04)
  • [47] Circulating tumor DNA for triple-negative breast cancer diagnosis and treatment decisions
    Saliou, Adrien
    Bidard, Francois-Clement
    Lantz, Olivier
    Stern, Marc-Henri
    Vincent-Salomon, Anne
    Proudhon, Charlotte
    Pierga, Jean-Yves
    EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2016, 16 (01) : 39 - 50
  • [48] Potential Management of Circulating Tumor DNA as a Biomarker in Triple-Negative Breast Cancer
    Shang, Mao
    Chang, Chunxiao
    Pei, Yanqing
    Guan, Yin
    Chang, Jin
    Li, HuiHui
    JOURNAL OF CANCER, 2018, 9 (24): : 4627 - 4634
  • [49] Circulating tumor cells in triple-negative and non-triple negative breast cancer patients show different genetic profiles
    Bittner, A-K
    Hoffmann, O.
    Hauch, S.
    Kimmig, R.
    Kasimir-Bauer, S.
    CANCER RESEARCH, 2016, 76
  • [50] Capecitabine metronomic chemotherapy combined with autologous CIK cell immunotherapy in the treatment of recurrent and metastatic triple-negative breast cancer
    Chen, Sipan
    Yang, Yaobo
    Jiao, Yang
    Sun, Hua
    Yan, Zhaoyong
    JOURNAL OF BUON, 2021, 26 (03): : 734 - 740